Synovial Fibroblast 3.2: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis-diagnosed donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 2 of 2) - Dataset (ID:20235)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA1869 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | GRO-a | 7190.5 | 58 | |
N2759 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | GRO-a | 1798.0 | 47 | |
N2759 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | GRO-a | 15120.5 | 60 | |
RA1931 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | GRO-a | 332.0 | 70 | |
RA1931 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | GRO-a | 11443.0 | 67 | |
N2586 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | GRO-a | 709.5 | 66 | |
N2586 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | GRO-a | 16197.0 | 55 | |
RA1869 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | GRO-a | 20211.0 | 45 | |
RA1869 | IL-1 alpha | 100 | ng/mL | 3 | GRO-a | 3874.0 | 62 | ||||
N2759 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | GRO-a | 20859.5 | 46 | |
N2759 | IL-1 alpha | 100 | ng/mL | 3 | GRO-a | 20131.0 | 48 | ||||
RA1931 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | GRO-a | 20256.0 | 35 | |
RA1931 | IL-1 alpha | 100 | ng/mL | 3 | GRO-a | 19961.0 | 53 | ||||
N2586 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | GRO-a | 20074.0 | 43 | |
N2586 | IL-1 alpha | 100 | ng/mL | 3 | GRO-a | 21178.5 | 48 | ||||
RA1869 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 3 | GRO-a | 45.0 | 41 | |
RA1869 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 3 | GRO-a | 1815.5 | 60 | |
N2759 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 3 | GRO-a | 1366.0 | 61 | |
N2759 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 3 | GRO-a | 7890.5 | 62 | |
RA1931 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 3 | GRO-a | 1002.5 | 54 | |
RA1931 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 3 | GRO-a | 4249.5 | 48 | |
N2586 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 3 | GRO-a | 837.0 | 61 | |
N2586 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 3 | GRO-a | 7711.5 | 68 | |
RA1869 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 3 | GRO-a | 8590.0 | 63 | |
RA1869 | TNF-a | 100 | ng/mL | 3 | GRO-a | 6996.0 | 57 |